UK markets open in 4 hours 23 minutes
  • NIKKEI 225

    28,790.45
    +779.52 (+2.78%)
     
  • HANG SENG

    28,447.95
    -41.05 (-0.14%)
     
  • CRUDE OIL

    73.64
    -0.02 (-0.03%)
     
  • GOLD FUTURES

    1,785.00
    +2.10 (+0.12%)
     
  • DOW

    33,876.97
    +586.89 (+1.76%)
     
  • BTC-GBP

    23,424.78
    -1,965.34 (-7.74%)
     
  • CMC Crypto 200

    785.77
    -64.57 (-7.59%)
     
  • ^IXIC

    14,141.48
    +111.10 (+0.79%)
     
  • ^FTAS

    4,026.96
    +24.89 (+0.62%)
     

argenx to Present at Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.


June 1, 2021

Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that members of management will participate in the following upcoming investor conferences:

  • Goldman Sachs 42nd Annual Global Healthcare Conference. Fireside chat on Tuesday, June 8, 2021 at 2:10 p.m. ET.

  • JMP Securities Life Sciences Conference. Fireside chat on Wednesday, June 16, 2021 at 11:00 a.m. ET.

  • J.P. Morgan European Healthcare Conference. Management will participate in investor meetings on Thursday, June 17, 2021.

  • Raymond James Human Health Innovation Conference. Management will participate in a panel discussion on Tuesday, June 22, 2021 at 12:00 p.m. ET.

Additional information regarding these events will be available on the Company’s website at www.argenx.com.

About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, Japan, and Switzerland. For more information, visit https://www.argenx.com/ and follow us on LinkedIn at https://www.linkedin.com/company/argenx/ and Twitter at https://twitter.com/argenxglobal.

For further information, please contact:

Media:

Kelsey Kirk
kkirk@argenx.com

Joke Comijn
jcomijn@argenx.com

Investors:

Beth DelGiacco
bdelgiacco@argenx.com

Michelle Greenblatt
mgreenblatt@argenx.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting